The purpose of this study was to formulate and validate a new green high-performance liquid chromatography-ultraviolet (HPLC)-UV method for quick quantification of rosuvastatin calcium (ROC) in standard drugs. The results showed a combination of ethanol:methanol:ethyl acetate (6:3:1 v/v) at a rate of 1.0 ml/min to be the best for identifying ROC and its separation from its breakdown products. The identification of ROC was achieved using a NUCLEODUR 150 mm × 4.6 mm RP C8 column packed using 5 μm filler as the stationary phase and detection was performed at 254 nm. The technique developed was checked for linearity, selectivity, accuracy, precision, robustness and sensitivity as well as specificity. The usefulness of the proposed process was confirmed by analyzing ROC in a prepared self-nanoemulsifying drug delivery system (SNEDDS) and over-the-counter products. The amount of ROC in SNEDDS was found to be 98.38%. The HPLC-UV system we developed effectively determined the ROC peak along with its breakdown products which confirmed the stability-indicating property of the projected system. The system could also be used to compare the solubility of rosuvastatin nanoparticles in standard drugs. These outcomes indicated that the developed HPLC could be effectively used for the regular investigation of ROC in standard drugs, various pharmaceutical formulations and drug release samples.
Introduction

Rosuvastatin calcium (ROC) is chemically known as (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]
pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid calcium salt (2:1) ( Figure 1 ). It is a synthetic, orally active and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase with significant and specific low-density lipoprotein cholesterol-lowering activity in vitro and in vivo [1] [2] [3] . It is also used in the treatment of osteoporosis, benign prostatic hyperplasia and Alzheimer's disease [4] .
Several assays for the quantification of rosuvastatin in bulk drugs, in marketed formulations as well as in various biological matrices such as rat plasma, rabbit plasma, human plasma, serum, etc. have been documented. Rosuvastatin has been determined chemometrically [5] [6] [7] in marketed formulations. A high-performance liquid chromatography (HPLC) system equipped with ultraviolet (UV) detection was previously used efficiently for ROC analysis in biological samples [8] [9] [10] [11] , in pharmaceuticals [12] [13] [14] [15] and in both biological samples and pharmaceuticals [16, 17] . ROC was determined in marketed products by capillary zone electrophoresis [18] and micellar electrokinetic chromatography [19] . There are very few HPLC research papers that have discussed ROC pharmacokinetics in volunteers [20, 21] and rats [22] .
The oral bioavailability of ROC is 20% because of its low aqueous solubility due to its crystalline nature and it being extensively metabolized by liver via oxidation, lactonization and glucuronidation. The by-products or metabolites are eliminated by biliary secretion in addition to direct secretion from the blood to the intestine [23] [24] [25] . For these reasons, enhancing the solubility and bypassing the hepatic metabolism of ROC is an advantageous approach to enhancing its therapeutic performance. Lipid-based drug delivery systems have attained increasing attention in the oral administration of inadequately bioavailable drugs as a means of bypassing the drug passage in the hepatic portal vein and consequently its hepatic degradation [26] . A self-emulsifying drug delivery system is one of the lipid based drug delivery approaches that is being used at present because of its advantages, i.e. it provides a greater interfacial region for partitioning of the drug between oil and GI fluid [27] . The developed method was utilized for the determination of ROC in a self nano-emulsifying drug delivery system (SNEDDS) to check its applicability.
In spite of their toxicity, the most frequently employed solvents as the mobile phase in liquid chromatography were volatile organic solvents like acetonitrile. These solvents need special treatment before being released into the environment. One of the 12 principles of green chemistry emphasizes the use of alternative solvents to minimize the negative environmental impact of toxic solvents [28] . A search through literature over the last 15 years clearly shows that the application of environmentally benign and greener solvents has increased exponentially [29] . As far as liquid chromatography is concerned, ethanol possesses most of the favorable properties of methanol and acetonitrile including its much lower environmental toxicity as well as ease of disposal [30] . In the case of ethyl acetate, it is mentioned in the official document (USEPA 1986) prepared by the Office of Research and Development under the Resource Conservation and Recovery Act of USA that it is totally biodegradable which has been proved by many biological oxygen demand experiments [31] . Moreover, Capello et al. [32] proposed a concept for assessing the environmental impact of solvents that is based on the application of two environmental evaluation methods with varying scopes. The first one is the environmental, health and safety assessment method [33] that evaluates the potential hazards of chemicals. The other method, the life-cycle assessment method [34] was employed for a complete assessment of releases to the environment as well as resource use over the full life-cycle of a solvent. Based on this study, it was found that methanol as well as ethanol was environmentally more favorable as compared to other commonly used solvents like acetonitrile. To our disappointment, despite possessing environmentally encouraging properties such as a benign nature, lessor non-inflammability, non-aggressiveness, decomposing easily and being economical, the full potential of alternative solvents such as ethyl acetate, ethanol etc. along with their mixtures as the mobile phase for the investigation of active pharmaceutical ingredients, has not been exploited [35] [36] [37] [38] [39] . The present study was performed keeping the above information in mind by employing environmentally benign solvents for chromatographic purposes.
Materials and methods
Chemicals and reagents
Rosuvastatin (purity 99.9%) was purchased from Riyadh Pharma (Riyadh, Saudi Arabia). HPLC grade ethyl acetate, methanol and ethanol were procured from BDH Laboratory supplies (Liverpool, UK). The rest of the reagents and chemicals employed were of analytical reagent quality. Commercial tablets of ROC 10 mg (AstraZeneca, Chicago, USA) were obtained from the domestic market of Riyadh, Kingdom of Saudi Arabia. A ROC SNEDDS was prepared in the laboratory by the spontaneous emulsification method using eucalyptus oil (Sigma Aldrich, Saint Louis, MO, USA) as the oil phase, triton-X 100 as surfactant (Sigma Aldrich, Saint Louis, MO, USA), Transcutol HP (Gattefosse, lyon, France) as co-surfactant, and demineralized water as the aqueous phase.
Instrumentation and chromatographic conditions
The chromatographic system used the software Millennium (Artisan Technology Group®, Champaign, IL, USA), version 32. The column used for this study is a NUCLEODUR (MACHEREY-NAGEL GmbH & Co., Düren, Germany) 150 mm × 4.6 mm RP C8 packed using 5 μm filler as the stationary phase. The eluent was composed of ethanol:methanol:ethyl acetate (6:3:1 v/v). The mobile phase was made to flow with 1.0 ml/ min rate and recognition was performed at 254 nm. Samples of 10 μl were introduced into the system employing a Waters Autosampler (Waters Corporation, Milford, MA, USA). The analysis of ROC was done at room temperature of 22 ± 1°C, using a Waters HPLC system 1515 isocratic (Waters, USA) pump, a 717 Autosampler (Waters Corporation, Milford, MA, USA), quaternary LC-10AVP pumps (Waters Corporation, Milford, MA, USA), a programmable UV-visible variable-wavelength detector (Waters Corporation, Milford, MA, USA), an SPD-10AVP column oven (Waters Corporation, Milford, MA, USA), a SCL 10AVP system controller (Shimadzu, Japan) and an inline vacuum degasser (Waters Corporation, Milford, MA, USA). The mobile phase consisted of ethanol:methanol:ethyl acetate (6:3:1 v/v). Samples of 10 μl were introduced into the system using a 717 Autosampler.
Preparation of rosuvastatin stock solution
A linearity curve for ROC was plotted from 0.1 μg/ml concentration to 100 μg/ml. Working dilutions in the desired range were prepared from the stock solution (100 μg/ml) by suitably mixing the requisite aliquots with the eluent to get the desired concentration.
Method development
Several combinations of hybrid organic/hydro-organic solvent mixtures as eluent were utilized for developing an appropriate green HPLC method for the estimation of rosuvastatin in its standard form. Various parameters were kept in mind while deciding the suitability of any solvent or mixture of solvents to be used as the mobile phase such as appropriateness for stability studies, sensitivity of the developed method, time consumed for the analysis, peak parameters, mutual miscibility of the constituent solvents and the economy of the solvents. Depending upon the criteria mentioned above, various eluents such as methanol-water, methanol-phosphate buffer, acetonitrile-phosphate buffer, methanol-sodium perchlorate buffer and acetonitrile-sodium perchlorate buffer along with ethanol and ethyl acetate in varying proportions were tried. Among the various solvent systems tried for HPLC quantification, a combination of ethanol:methanol:ethyl acetate (6:3:1 v/v) was preferred as the most suitable mobile phase for subsequent investigations.
Validation studies
The newly developed green HPLC method was validated for various parameters such as selectivity, linearity, precision, accuracy, robustness, sensitivity and specificity. Freshly made dilutions from 0.1 μg/ml concentration to 100 μg/ml were used for plotting of linearity curves. The solvent system containing ethanol:methanol:ethyl acetate (6:3:1 v/v) was dispatched at 1.0 ml/min for bringing the column to equilibrium and the baseline was constantly observed and monitored throughout the entire procedure. The drug ROC was detected at 254 nm. The freshly prepared sample solutions were introduced into the system in multiples of three and the chromatographic reactions as peak areas were documented using the HPLC system for all solutions and calibration was obtained by plotting concentration against peak area. The selectivity of the system created was evaluated by cyclic injections of a designated concentration of ROC (10 μg/ml). The fluctuations in chromatographic response, i.e. retention time (Rt) and peak area, were documented for the determination of selectivity.
The standard addition method was used to assess the accuracy of the developed process. The selected target ROC sample (10 μg/ml) was mixed with four different concentrations (0%, 50%, 100% and 150%) of surplus drug standard solution and the resultant drug solutions were reanalyzed by the newly developed HPLC system. Each test was done three times. Percent recovery (%), standard deviation (RSD, %), and standard error for all selected concentrations were computed.
The precision of the newly developed system was evaluated on two levels, i.e. intraday (repeatability) precision and interday (intermediate) precision. The intraday precision of the projected green HPLC system was evaluated by the quantification of three selected concentrations of ROC solution (10, 25, 50 μg/ml) three times on the same date. However, when evaluating the intermediate precision, the samples were evaluated on 3 different days.
The robustness of the developed HPLC method was determined to evaluate the effect of deliberate changes made in the chromatographic conditions on the analysis of ROC. The 10 μg/ml concentration of ROC was preferred for this study. The robustness of the projected HPLC scheme was examined by slightly increasing (from 1.0 to 1.20 ml/min) as well as decreasing (from 1.0 to 0.80 ml/min) the rate of flow of the mobile phase, the wavelength at which recognition has to be performed from 254 to 245 and 270 nm and by varying the ratio of ethanol, methanol and ethyl acetate in the mobile phase.
Forced degradation studies
For the estimation of the stability-indicating characteristic as well as specificity of this developed method, a target concentration was exposed to diverse stressful conditions such as acidic stress, basic stress and oxidative as well as thermal stress. In the cases of acid stimulated, base stimulated and oxidative stress, selected concentrations (10 μg/ml) of freshly prepared ROC were mixed in 1:4 ratio with 0.1 m HCl, 0.1 m NaOH and 30% hydrogen peroxide (H 2 O 2 ), respectively, and placed in a hot air oven for 2 days at 50°C. Whereas in the case of thermal stress, 5 ml of the same target concentration of ROC was placed in a hot air oven for 2 days at 50°C.
Marketed product analysis
Commercially available formulations in the form of tablets were well compressed to a powdered state. Correctly weighed fractions of the powder equivalent to 5 mg, 25 mg and 50 mg of rosuvastatin were put into a 50 ml volumetric flask. Methanol (about 30 ml) was added to the flask followed by sonication in an ultrasonic bath for 3 min. After sonication, about 20 ml of methanol was further added to make up 50 ml and sonicated for 5 min. The solution was then filtered using a 0.45 μm nylon filter and after discarding the first few ml the filtrate was collected. Five milliliters of this filtrate were transferred to a 50 ml volumetric flask, diluted to volume with diluent and stirred suitably for proper mixing.
Application of green HPLC process for the analysis of rosuvastatin in SNEDDS 2.8.1 Preparation of rosuvastatin in SNEDDS:
After the selfemulsifying region was recognized, the preferred constituent ratios of SNEDDS were chosen for drug inclusion and further optimization. Ten milligrams of the drug and the mixed surfactant and co-surfactant were incorporated in their determined ratios into the oil phase containing the drug. Finally a homogeneous mixture was obtained using a vortex mixer. The prepared ROC SNEDDS was kept in a tightly closed bottle at 25°C and these stable formulations were subjected to further studies, i.e. dilution studies, droplet size analysis, self-emulsification time, particle size as well as zeta potential analysis.
Analysis of rosuvastatin in SNEDDS:
The authenticity of the green HPLC system was ascertained by using it for the evaluation of rosuvastatin in SNEDDS. A SNEDDS formulation of rosuvastatin was prepared in our laboratory by the spontaneous emulsification method using eucalyptus oil as the oil phase, triton-X 100 as surfactant, TranscutolHP as co-surfactant, and demineralized water as the aqueous phase. To analyze the amount of rosuvastatin in the prepared SNEDDS (having 05 μg/ml of rosuvastatin-single dose), SNEDDS (1 ml) was properly mixed with eluent to make 100 ml. The resultant solution was subsequently sonicated for 10 min and the sample thus obtained was evaluated for the amount of rosuvastatin present in SNEDDS [26] . The interference by nanoemulsion components in analyzing rosuvastatin in SNEDDS was also explored using the suggested method.
Application of green HPLC process for the analysis of rosuvastatin in solubility samples
The strength of the green HPLC process was also acknowledged by using it to determine the solubility of standard ROC drugs and laboratory prepared ROC nanoparticles (ROC-NPs) in water. The solubility (as mole fraction) of ROC in water and ROC-NPs was determined by using the Higuchi and Connors method at 298.15 K [40] . The excess amount of ROC and ROC-NPs was added into a known quantity of water. The mixtures were vortexed for 10 min and transferred to a biological shaker (Julabo, PA) for continuous shaking at 100 rpm for 72 h. The rest of the procedure was adopted from our recently published articles [41, 42] . The amount of ROC and ROC-NPs present in the water was determined using the proposed HPLC method.
Results and discussion
Results
Of the various combinations of mixed organic/hydroorganic solvent systems as the mobile phase tried for the development of a suitable green HPLC method for the quantification of ROC in its standard drug compound, the combination of ethanol, methanol and ethyl acetate in 6:3:1 v/v ratio was selected as an environmentally friendly green eluent to achieve a fast and simple assay with a rational run time (5 min), appropriate Rt (1.52 ± 0.01 min) as well as a satisfactory tailing or asymmetry factor (Figure 2 ).
Method validation
Freshly made dilutions from 0.1 μg/ml concentration to 100 μg/ml were used for the plotting of linearity curves. Table 1 .
The fluctuations in chromatographic response, i.e. Rt and peak area, were recorded for selectivity determination. The magnitude of % RSD in peak area and Rt was found to be 0.33 and 0.54, respectively ( Table 2) .
The HPLC responses in terms of area for the estimation of accuracy were computed as % recovery as presented in 
Forced degradation studies
The stability indicating property of the developed scheme was estimated by exposing the ROC to different stress conditions such as acidic, basic, oxidative and thermal stress. The acidic stress condition was tolerated well by the ROC and 77.8% of the ROC was remaining in the acidic mixture sample and only 22.2% had degraded (Figure 3 ). The acidenforced breakdown product (peak 2 in Figure 3 ) was detected with an Rt of 2.84 min (Table 5 ). Only 14.3% of ROC remained in the alkaline sample and 85.7% had disintegrated in 48 h (Figure 4) . The base-induced breakdown stuffs (peaks 2 and 3 in Figure 4 ) were eluting with an Rt of 3.78 and 4.63 min, respectively. Only 5.75% of the ROC was persisting in the H 2 O 2 -induced stress sample and 94.25% had degraded ( Figure 5 ). The H 2 O 2 -generated degradation product (peak 2 in Figure 5 ) was seen to be eluting with an Rt of 3.47 min. In the case of thermal stress, 16.4% ROC was found to be present in the sample after 48 h exposure revealing its tendency to degradation on exposure to heat ( Figure 6 ). From the evaluation of peak areas of stored drug solution [when stored for 72 h in the optimized mobile phase at room temperature (25 ± 1°C) and under freezing conditions (4 ± 0.5°C)] and peak areas obtained from a freshly prepared solution of ROC, it was inferred that ≥99% of the ROC remained unchanged.
Relevance of developed RP-HPLC method for the evaluation of rosuvastatin in developed SNEDDS
On verifying the validity of the newly developed green chromatographic method by using it to estimate the amount of ROC in SNEDDS, it was found to be 98.38% (% RSD = 1.27). 
Relevance of developed RP-HPLC method for the determination of ROC & ROC-NPs solubility in water
When the developed method was used for the determination of solubility of standard ROC drugs and laboratory prepared ROC nanoparticles (ROC-NPs), the mole fraction solubility of ROC in water was recorded as 5.43 × 10 −6 at 298.15 K. However, the mole fraction solubility of ROC-NPs was recorded as 1.48 × 10 −2 at 298.15 K.
Discussion
During the chromatographic process improvement stage, employing methanol as well as ethanol in combination with a phosphate buffer as the eluent led to an asymmetric chromatographic response in the form of a peak having a larger tailing factor (>2) and fewer numbers of theoretical plates (<2000). Additionally, when acetonitrile coupled with a buffer was tried at various ratios at a flow rate of 1 ml/min, a chromatogram with a poor peak was the result. With the intention of getting a sharp peak response with an asymmetry factor <2 and fine sensitivity, an ethanol and ethyl acetate mixture was tested as an alternative eluent. Of the various compositions of ethanol and ethyl acetate tested, the binary mixture at 9:1% v/v proportion produced a better chromatogram with a sharp peak, satisfactory Rt and asymmetry factor <2. Furthermore, methanol in small proportions was added to reduce the viscosity of the mobile phase. Finally, a mixture of ethanol, methanol and ethyl acetate in 6:3:1 v/v ratio was selected as an environmentally friendly eluent to realize a fast and simple assay for ROC with a suitable analysis time (5 min), a fitting Rt (1.52 ± 0.01 min) as well as an acceptable tailing or asymmetry factor.
Method validation
The calibration curve prepared was assessed by means of linear least square analysis and the correlation coefficient. No noteworthy dissimilarity was found in the slopes of standard curves prepared (ANOVA, p > 0.05).
The selectivity of the proposed chromatographic method was evaluated by repetitive injections of ROC at 10 μg/ml concentration (the selected target concentration). The magnitude of SD and % RSD obtained in peak area as well as in Rt were found to be very small. The magnitude of % RSD in peak area and Rt clearly suggests the selectivity of the proposed analytical method.
The HPLC area responses for accuracy estimation were computed as % recovery and are shown in Table 3 . Excellent recoveries of the spiked drug indicated the accuracy of the proposed method. The outcome of repeatability (intraday precision) as well as intermediate precision was expressed in terms of % RSD. The obtained % RSD values for repeatability and intermediate precision studies indicated that the proposed chromatographic system is precise (low value of RSD, i.e. <2% is the indication of precision of the proposed method). In the case of the robustness study, the values obtained for the statistical parameters of the chromatographic responses for all variations (mobile phase constitution, detection wavelength and flow rate) at the target concentration level of 10 μg/ml are shown in Table 6 . The small magnitude of % RSD and standard error obtained as a result of introducing small calculated variations in the eluent composition, detection wavelength and flow rate suggested the robustness of the developed system. 
Forced degradation studies
The stability-indicating character as well as the specificity of the projected green chromatographic method was evaluated by subjecting the selected sample of ROC to various stress conditions. On exposure to the acidic stress condition, ROC was observed to be stable and more than 75% of the total ROC present in the solution was remaining in the acid-induced stress sample. The ROC had degraded into one major component which was detected with an Rt of 2.84 min. Nevertheless, it had degraded enough in the alkaline 0.1 m NaOH solution indicating its instability in alkaline conditions. The ROC had almost completely degraded in the oxidative stress (H 2 O 2 ) conditions showing its vulnerability to degradation in these conditions (30% H 2 O 2 ). It was also found to be susceptible to degradation when exposed to thermal stress as was inferred from the low amount of the drug found in this sample.
Solution stability
ROC was found to be sufficiently stable in solution form as suggested by the comparison between the peak area values as well as the symmetry of the peaks acquired from the freshly made solution with that of the solution kept for 72 h at room temperature (25 ± 1°C) and freezing conditions (4 ± 0.5°C).
Relevance of developed RP-HPLC method for the evaluation of rosuvastatin in developed SNEDDS
The developed green reverse-phase liquid chromatographic method was found to be fast, responsive and fitting for the quantitative determination of ROC. As a result, this method was employed for the analysis of ROC in laboratory prepared w/o SNEDDS. From the sufficiently high assay value and small % RSD (1.27) of ROC in the formulation, it can be inferred that the developed process might be apt for the regular investigation of ROC in SNEDDS formulations. The chromatogram of ROC extracted from this formulation was similar when compared to that of pure ROC, displaying the purity of peak in examined formulations.
Relevance of developed RP-HPLC method for the determination of ROC & ROC-NPs solubility in water
The developed green RP-HPLC method was found to be suitable for the routine analysis of ROC. Hence, this method was applied for the determination of solubility of ROC and ROC-NPs in water. The significant enhancement in solubility of ROC was observed in ROC-NPs in comparison with its solubility in water. The proposed RP-HPLC method indicated the suitability of this method in the determination of the solubility of ROC.
Conclusion
The 
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